BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
Number Cited Articles
1
Ian K. Mangion, Cheng-yi Chen, Hongmei Li, Peter Maligres, Yonggang Chen, Melodie Christensen, Ryan Cohen, Ingyu Jeon, Artis Klapars, Shane Krska, Hoa Nguyen, Robert A. Reamer, Benjamin D. Sherry, Ilia Zavialov. Enantioselective Synthesis of an HCV NS5a AntagonistOrganic Letters 2014; 16(9): 2310 doi: 10.1021/ol500971c
2
Jeffrey L. Romine, Denis R. St. Laurent, John E. Leet, Scott W. Martin, Michael H. Serrano-Wu, Fukang Yang, Min Gao, Donald R O’Boyle, Julie A. Lemm, Jin-Hua Sun, Peter T. Nower, Xiaohua (Stella) Huang, Milind S. Deshpande, Nicholas A. Meanwell, Lawrence B. Snyder. Inhibitors of HCV NS5A: From Iminothiazolidinones to Symmetrical StilbenesACS Medicinal Chemistry Letters 2011; 2(3): 224 doi: 10.1021/ml1002647
3
José M. Ladero. Optimizing dosage and duration therapy for chronic hepatitis C «difficult-to-treat patients»Annals of Hepatology 2008; 7(4): 392 doi: 10.1016/S1665-2681(19)31846-0
4
Xi Zong, Jin Cai, Junqing Chen, Peng Wang, Gaoxin Zhou, Bo Chen, Wei Li, Min Ji. Design and synthesis of imidazole N–H substituted amide prodrugs as inhibitors of hepatitis C virus replicationBioorganic & Medicinal Chemistry Letters 2015; 25(16): 3147 doi: 10.1016/j.bmcl.2015.06.006
5
Min Gao, Richard E. Nettles, Makonen Belema, Lawrence B. Snyder, Van N. Nguyen, Robert A. Fridell, Michael H. Serrano-Wu, David R. Langley, Jin-Hua Sun, Donald R. O’Boyle II, Julie A. Lemm, Chunfu Wang, Jay O. Knipe, Caly Chien, Richard J. Colonno, Dennis M. Grasela, Nicholas A. Meanwell, Lawrence G. Hamann. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effectNature 2010; 465(7294): 96 doi: 10.1038/nature08960
6
Seyed Moayed Alavian, Seyed Vahid Tabatabaei, Bita Behnava, Nastaran Mahboobi. Optimal Duration of Treatment for HCV Genotype 1 Infection in Slow Responders: A Meta-AnalysisHepatitis Monthly 2011; 11(8): 612 doi: 10.5812/kowsar.1735143X.2187
7
Phil McEwan, Ray Kim, Yong Yuan. Assessing the Cost Utility of Response-Guided Therapy in Patients with Chronic Hepatitis C Genotype 1 in the UK Using the MONARCH ModelApplied Health Economics and Health Policy 2013; 11(1): 53 doi: 10.1007/s40258-012-0002-0
8
Paul M. Scola, Alan Xiangdong Wang, Andrew C. Good, Li-Qiang Sun, Keith D. Combrink, Jeffrey A. Campbell, Jie Chen, Yong Tu, Ny Sin, Brian L. Venables, Sing-Yuen Sit, Yan Chen, Anthony Cocuzza, Donna M. Bilder, Stanley D’Andrea, Barbara Zheng, Piyasena Hewawasam, Min Ding, Jan Thuring, Jianqing Li, Dennis Hernandez, Fei Yu, Paul Falk, Guangzhi Zhai, Amy K. Sheaffer, Chaoqun Chen, Min S. Lee, Diana Barry, Jay O. Knipe, Wenying Li, Yong-Hae Han, Susan Jenkins, Christoph Gesenberg, Qi Gao, Michael W. Sinz, Kenneth S. Santone, Tatyana Zvyaga, Ramkumar Rajamani, Herbert E. Klei, Richard J. Colonno, Dennis M. Grasela, Eric Hughes, Caly Chien, Stephen Adams, Paul C. Levesque, Danshi Li, Jialong Zhu, Nicholas A. Meanwell, Fiona McPhee. Discovery and Early Clinical Evaluation of BMS-605339, a Potent and Orally Efficacious Tripeptidic Acylsulfonamide NS3 Protease Inhibitor for the Treatment of Hepatitis C Virus InfectionJournal of Medicinal Chemistry 2014; 57(5): 1708 doi: 10.1021/jm401840s
9
Nipaporn Pichetshote, Erik Groessl, Helen Yee, Samuel B. Ho. Optimizing the Dose and Duration of Therapy for ChronicHepatitis CGut and Liver 2009; 3(1): 1 doi: 10.5009/gnl.2009.3.1.1